Therapeutic Asset Ratings
534 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Fpi-2053
Cancer
AstraZeneca
P1
C
(36)
ft825
Cancer
Fate Therapeutics
P1
C
(36)
Gamitrinib
Cancer
Fox Chase Cancer Center
P1
C
(36)
Gensci122
Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
P1
C
(36)
Grc 54276
Cancer
Glenmark Specialty S.A.
P1
C
(36)
gs-5319
Cancer
Gilead Sciences
P1
C
(36)
Gtb-5550
Cancer
Masonic Cancer Center, University of Minnesota
P1
C
(36)
h1710 for
Cancer
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
P1
C
(36)
hb0030
Cancer
Huabo Biopharm Co., Ltd.
P1
C
(36)
hc010
Cancer
HC Biopharma Inc.
P1
C
(36)
hcb101
Cancer
FBD Biologics Limited
P1
C
(36)
hcb301
Cancer
FBD Biologics Limited
P1
C
(36)
hg381
Cancer
HitGen Inc.
P1
C
(36)
hlx23
Cancer
Shanghai Henlius Biotech
P1
C
(36)
hs-10381
Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(36)
hs-10386
Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(36)
hs-20089
Cancer
Hansoh BioMedical R&D Company
P1
C
(36)
hs-20108 monotherapy
Cancer
Hansoh BioMedical R&D Company
P1
C
(36)
hs269
Cancer
Zhejiang Hisun Pharmaceutical Co. Ltd.
P1
C
(36)
hy-0102
Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
P1
C
(36)
il12-l19l19
Cancer
Philogen S.p.A.
P1
C
(36)
ilb2109
Cancer
Innolake Biopharm
P1
C
(36)
Ilb-3101
Cancer
Innolake Biopharm
P1
C
(36)
imc008
Cancer
Changhai Hospital
P1
C
(36)
imm2520
Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
P1
C
(36)
Showing 351 to 375 of 534 assets
Previous
Page 15 of 22
Next
